Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Archive ouverte

Roussel, Mikaël | Ferrant, J. | Reizine, F. | Le Gallou, S. | Dulong, J. | Carl, S. | Lesouhaitier, M. | Gregoire, M. | Bescher, N. | Verdy, C. | Latour, M. | Bézier, I. | Cornic, M. | Vinit, A. | Monvoisin, C. | Sawitzki, B. | Leonard, S. | Paul, S. | Feuillard, J. | Jeannet, R. | Daix, T. | Tiwari, V.K., K | Tadié, Jean-Marc | Cogné, Michel | Tarte, Karin

Edité par CCSD ; Cell Press -

International audience. Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COVID-19), requiring admission to the intensive care unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, here, we build 3 cohorts of patients categorized in COVID-19ARDS, COVID-19ARDS, and COVID-19ARDS, and compare, by high-dimensional mass cytometry, their immune landscape. A cell signature associating S100A9/calprotectin-producing CD169 monocytes, plasmablasts, and Th1 cells is found in COVID-19ARDS, unlike COVID-19ARDS patients. Moreover, this signature is essentially shared with COVID-19ARDS patients, suggesting that severe COVID-19 patients, whether or not they experience ARDS, display similar immune profiles. We show an increase in CD14HLA-DR and CD14CD16 monocytes correlating to the occurrence of adverse events during the ICU stay. We demonstrate that COVID-19-associated ARDS displays a specific immune profile and may benefit from personalized therapy in addition to standard ARDS management.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion